What leverage considerations apply to trading IDX as a stock CFD on CoinUnited?

Stock CFDs on CoinUnited carry a standard trading fee of 0.070% per side. With post-earnings volatility typically elevated, position sizing relative to leverage is critical — using higher leverage amplifies both upside from continued momentum and downside if the move fades.

Does this result have a read-through for other ASX healthcare stocks?

Yes, modestly — the result validates the consolidation and synergy thesis in diagnostic imaging, which could lift sentiment for sector peers. However, IDX-specific factors (Capitol Health integration) are the primary driver rather than a broad sector macro tailwind.

What would invalidate the bullish case from here?

Key risks include failure to sustain the ~21% EBITDA margin in FY27, integration costs re-emerging, or macro headwinds to healthcare utilisation in Australia. A deterioration in the January revenue run-rate beyond FY27 guidance would be the clearest negative signal.

How does the ASX 200's healthcare weighting factor into this?

IDX is a small-to-mid cap name with limited direct weight in the S&P/ASX 200, so index-level impact is minimal. The trade is primarily a stock-specific and sector-sentiment play rather than a broad index catalyst.

روابط سريعة

Integral Diagnostics Surges 6.6% as FY2026 Earnings Beat on Capitol Health Synergies

تم النشر: 2026-08-25 03:11:10 UTC

لقطة بيانات

FY2026 Revenue

~AUD 788.7m (+25.6% YoY)

Operating NPAT

~AUD 47.4m (+50.1% YoY)

Merger Synergies

~AUD 14m annually (target: AUD 10m+)

Operating EBITDA

~AUD 164.8m (~20.9% margin)

Share Price Reaction

+6.6% on results day

Operating Free Cash Flow

~AUD 106.4m (+30.7% YoY)

النقاط الرئيسية

•FY2026 operating NPAT surged 50.1% to ~AUD 47.4m, with revenue up 25.6% to ~AUD 788.7m — a broad-based beat.
•Capitol Health merger synergies hit ~AUD 14m annually, exceeding the AUD 10m+ target and reducing integration execution risk.
•Operating free cash flow of ~AUD 106.4m and net debt/EBITDA of ~2.5x provide balance sheet flexibility for further M&A and dividend growth.
•January 2026 like-for-like revenue growth of 7.8% signals early FY27 momentum, supporting the case for analyst estimate upgrades.
•The 6.6% single-day move suggests the market was under-positioned — watch for consensus upgrades as the secondary catalyst.

The S&P/ASX 200 Index opened at 9114.1 and closed at 9158.0, marking a 0.48% increase over the last 24 hours. The index reached a high of 9182.9 and a low of 9077.7 during this period, indicating a relatively stable trading range. Integral Diagnostics experienced a notable surge of 6.6% following the announcement of FY2026 earnings that exceeded expectations, attributed to synergies with Capitol Health. For leveraged trading, a long position can be entered at 9158.0, with tiered investments at 100, 500, and 1000 units. This upward movement in the index reflects a positive sentiment in the market, with Integral Diagnostics standing out as a significant performer today. — S&P/ASX 200 Index shows a 0.48% increase, with Integral Diagnostics surging 6.6%.

According to an earnings call transcript reported by Investing.com, Integral Diagnostics Limited (ASX: IDX) delivered a materially strong FY2026 result, triggering a 6.6% single-session share price ra

Event Analysis

According to an earnings call transcript reported by Investing.com, Integral Diagnostics Limited (ASX: IDX) delivered a materially strong FY2026 result, triggering a 6.6% single-session share price rally. Full-year revenue reached approximately AUD 788.7m — up 25.6% year-on-year — while operating EBITDA climbed ~30% to AUD 164.8m (margin: ~20.9%). The headline number was operating NPAT of ~AUD 47.4m, up 50.1% from FY25's AUD 31.6m, driven heavily by the integration of Capitol Health.

The strategic significance here goes beyond headline growth: annual synergies from the Capitol Health merger reached ~AUD 14m, exceeding the initial target of at least AUD 10m. This matters because ahead-of-plan synergy delivery de-risks the integration thesis, strengthens confidence in margin durability, and raises the prospect of earnings upgrades. For a mid-cap healthcare services name, these are precisely the signals that can re-rate a stock — not just move it for a day. Operating free cash flow of ~AUD 106.4m (up 30.7%) and a net debt/EBITDA of ~2.5x give the balance sheet room to pursue further bolt-on M&A while growing dividends.

What distinguishes this result from a standard beat is the quality composition: margin expansion (+~80 bps), cash flow conversion, and synergies that compound into future periods. As covered in our guide on earnings beats across sectors, durable margin improvement is the key differentiator between a one-day pop and a sustained re-rating. Early FY27 momentum adds further credibility — January 2026 showed 7.8% constant-currency like-for-like revenue growth, per the research report.

What This Means for Traders

The 6.6% single-day move signals the market was under-positioned heading into the print, likely discounting integration risk that has now been demonstrably resolved. The immediate question for traders is whether this is a catalyst for a sustained re-rating or a mean-reversion opportunity. Given the quality of the result — strong cash flow, rising dividends, and synergies exceeding plan — the fundamental case supports the former. Traders should monitor whether analyst consensus earnings estimates are upgraded in the days following, as that is typically the secondary catalyst that extends post-earnings momentum. For context on trading this type of post-report dynamic, see how to trade post-report surges.

The read-through for the broader Australian healthcare services and diagnostic imaging sector is modestly positive. The Capitol Health consolidation thesis is now validated, which could encourage similar M&A or re-rate peers. The S&P/ASX 200 Index has indirect exposure via healthcare sector weighting, though IDX is a small-to-mid cap name and the index-level impact is limited. Traders focused on the diversified sector earnings beat wave theme may find IDX consistent with that playbook. Volatility is likely to normalise rapidly post-earnings unless further guidance upgrades emerge.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.

الأسئلة الشائعة

Given the quality of the result — margin expansion, cash flow beat, and above-target synergies — the fundamental case supports the move holding and potentially extending if analysts upgrade consensus estimates. Mean-reversion risk is lower than typical given the synergy de-risking.